1. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011 Feb 10;29(5):573-82. doi: 10.1200/JCO.2010.29.8711.
2. Меликян А.Л., Суборцева И.Н. Биология миелопролиферативных заболеваний Клиническая онкогематология. 2016; 9 (3): 314-325.
3. R.C.Skoda, A. Duek, J. Grisouard. Pathogenesis of myeloproliferative neoplasms. Experimental Hematology. Volume 43, Issue 8, August 2015, Pages 599-608 https://doi.org/10.1016/j.exphem.2015.06.007
4. Schischlik F., Kralovics R. Mutations in myeloproliferative neoplasms - their significance and clinical use. Expert Rev Hematol. 2017 Nov;10(11):961-973. doi: 10.1080/17474086.2017.1380515. Epub 2017 Sep 25.
5. W. Vainchenker, Franc, Delhommeau,1,2,4 Stefan N. Constantinescu,5,6 and Olivier A. Bernard. New mutations and pathogenesis of myeloproliferative neoplasms. BLOOD, 2011. 118(7):1723-1735; doi: https://doi.org/10.1182/blood-2011-02-292102
6. H.C.Hasselbalch,M.E.Bj0rn.MPNs as Inflammatory Diseases:The Evidence, Consequences, and Perspectives. Mediators Inflamm. 2015;2015:102476. doi: 10.1155/2015/102476.
7. Mehta J., Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014 Mar;55(3):595-600. doi: 10.3109/10428194.2013.813500. Epub 2013 Jul 29.
8. Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Миелопролиферативные новообразования. Монография. С-Пет. 2016; 298
9. D.A. Arber, A. Orazi, R. Hasserjian, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia // Blood. - 2016. - Vol.127, №20. - P. 2391-2405.
10. Robyn M. Emanuel, Amylou C. Dueck, Holly L. Geyer, Jean-Jacques Kiladjian, Stefanie Slot, Sonja Zweegman,Peter A.W. te Boekhorst, Suzan Commandeur, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, et al. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. J Clin Oncol. 2012; 30(33): 4098-4103. doi: 10.1200/JCO.2012.42.3863
11. Vannucchi A. M., T. Barbui, F. Cervantes, C. Harrison, J.-J. Kiladjian, N. Kroger, J. Thiele, Buske C. Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms: ESMO Clinical Practice Guidelines Ann Oncol (2015) 26 (suppl 5): v85-v99.
12. Agarwal M. B., Malhotra H., Chakrabarti P., Varma N., Mathews V., Bhattacharyya J., T. Seth, K. Gayathri, H. Menon, P. G. Subramanian, A. Sharma, M. Bhattacharyya, J. Mehta, A. K. Vaid, S. Shah, S. Aggarwal, P. K. Gogoi, U. Agarwal, Varma. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia Indian J Med Paediatr Oncol. 2015 Jan-Mar; 36(1): 3-16. doi: 10.4103/0971-5851.151770
13. Busque L, Porwit A, Day R, Olney HJ, Leber B, Ethier V, Sirhan S, Foltz L, Prchal J, Kamel-Reid S, Karsan A, Gupta V. Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian MPN Group. Am J Clin Pathol. 2016 Oct;146(4):408-22. doi: 10.1093/ajcp/aqw131.
14. Hoffman R. et al. Hematology: Basic Principles and Practice E-Book 7th edition 2017 https://books.google.de/books?isbn=0323509711
15. Toros A. B., Gokcay S., Cetin G., Ar M. C., Karagoz Y., Kesici B. Portal Hypertension and Myeloproliferative Neoplasms: A Relationship Revealed. ISRN Hematol.Volume 2013, Article ID 673781, 5 pages http://dx.doi.org/10.1155/2013/673781
16. Pieri L., Guglielmelli P., Vannucchi A. M. Chronic Myeloproliferative Neoplasms: a Collaborative Approach. Mediterr J Hematol Infect Dis. 2010; 2(2): e2010017. Published online 2010 Jun 21. doi: 10.4084/MJHID.2010.017
17. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23(10):2224-2232
18. Michiels J. J., Berneman Z., Schroyens W. et al. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006; 32:589—604.
19. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013 Sep;27(9):1874-81. doi: 10.1038/leu.2013.163.
20. Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Practicerelevant revision of IPSET- thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.Blood Cancer J. 2015 Nov 27;5:e369. doi: 10.1038/bcj.2015.94.
21. Cervantes F. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009. 113(13). 2895-901.
22. Passamonti F., Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, Tefferi A. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15):2857-8. doi: 10.1182/blood-2010-06-293415.
23. Gangat N., Caramazza D., Vaidya R. et al. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology. 2011. 29(4). 392-7.
24. Vannucchi AM, P. Guglielmelli, Rotunno G, Pascutto C, Pardanani A. Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project // Blood. - 2014. - P. 405
25. Tefferi, P. Guglielmelli, C. Finke, et al. Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis // Blood. - 2014. -Vol.124. - P. 406.